Aliases & Classifications for Urticaria

MalaCards integrated aliases for Urticaria:

Name: Urticaria 12 76 29 55 6 15 73

Classifications:



External Ids:

Disease Ontology 12 DOID:1555
ICD9CM 35 708.8
ICD10 33 L50 L50.2 L50.9

Summaries for Urticaria

Disease Ontology : 12 A skin disease characterized by skin rash notable for pale red, raised and itchy bumps, located in the upper dermis.

MalaCards based summary : Urticaria is related to physical urticaria and cold urticaria, and has symptoms including abdominal pain, chest pain and constipation. An important gene associated with Urticaria is F12 (Coagulation Factor XII), and among its related pathways/superpathways are Immune response Fc epsilon RI pathway and NF-kappaB Signaling. The drugs Clarinex and Cetirizine have been mentioned in the context of this disorder. Affiliated tissues include the upper dermis, skin and testes, and related phenotypes are hematopoietic system and immune system

Wikipedia : 76 Hives, also known as urticaria, is a kind of skin rash with red, raised, itchy bumps. They may also burn... more...

Related Diseases for Urticaria

Diseases related to Urticaria via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 287)
# Related Disease Score Top Affiliating Genes
1 physical urticaria 33.9 ADGRE2 FCER1A MS4A2
2 cold urticaria 33.9 CMA1 NLRP3 PLCG2 RNASE3
3 dermatographia 33.3 FCER1A MS4A2
4 allergic rhinitis 29.7 HRH1 MS4A2 RNASE3
5 conjunctivitis 29.6 MS4A2 NLRP3 RNASE3
6 angioedema 29.2 C1S CPN1 F12 HNMT LTC4S PTGS1
7 ige responsiveness, atopic 29.0 FCER2 MS4A2 RNASE3
8 dermatitis, atopic 28.2 CMA1 FCER2 HRH1 MS4A2 RNASE3 SELE
9 asthma 26.1 FCER1A FCER2 HNMT HRH1 LTC4S MS4A2
10 vibratory urticaria 12.5
11 cholinergic urticaria 12.4
12 solar urticaria 12.4
13 urticaria, aquagenic 12.3
14 urticaria pigmentosa 12.3
15 allergic urticaria 12.1
16 papular urticaria 12.0
17 familial cold autoinflammatory syndrome 3 12.0
18 schnitzler syndrome 12.0
19 muckle-wells syndrome 12.0
20 familial cold autoinflammatory syndrome 1 12.0
21 nodular urticaria pigmentosa 11.9
22 maculopapular cutaneous mastocytosis 11.8
23 urticaria, familial localized heat 11.8
24 plaque-form urticaria pigmentosa 11.8
25 typical urticaria pigmentosa 11.8
26 familial cold autoinflammatory syndrome 11.4
27 mast cell disease 11.3
28 familial cold autoinflammatory syndrome 4 11.2
29 exercise-induced anaphylaxis 11.1
30 cutaneous mastocytosis 11.1
31 cryopyrin-associated periodic syndrome 11.1
32 dermographism, familial 10.9
33 fascioliasis 10.9
34 arthus reaction 10.8
35 carboxypeptidase n deficiency 10.8
36 netherton syndrome 10.8
37 familial cold autoinflammatory syndrome 2 10.8
38 deafness, autosomal dominant 34, with or without inflammation 10.8
39 paragonimiasis 10.8
40 cystic echinococcosis 10.8
41 diffuse cutaneous mastocytosis 10.8
42 hypersensitivity vasculitis 10.8
43 anca-associated vasculitis 10.8
44 cutaneous mastocytoma 10.8
45 episodic angioedema with eosinophilia 10.8
46 hypocomplementemic urticarial vasculitis 10.8
47 monoclonal mast cell activation syndrome 10.8
48 blepharoconjunctivitis 10.5 CMA1 RNASE3
49 aspirin resistance 10.4 PTGS1 PTGS2
50 erythema multiforme 10.3

Comorbidity relations with Urticaria via Phenotypic Disease Network (PDN):


Acute Cystitis Hypertension, Essential
Ischemic Heart Disease

Graphical network of the top 20 diseases related to Urticaria:



Diseases related to Urticaria

Symptoms & Phenotypes for Urticaria

UMLS symptoms related to Urticaria:


abdominal pain, chest pain, constipation, coughing, diarrhea, dyspepsia, edema, exanthema, fatigue, fever, halitosis, headache, heartburn, icterus, nausea and vomiting, pain, pelvic pain, pruritus, sciatica, syncope, chronic pain, welts, vertigo/dizziness, gastrointestinal gas, darier's sign, symptoms

MGI Mouse Phenotypes related to Urticaria:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.7 MS4A2 NLRP3 PLCG2 PTGS1 PTGS2 SELE
2 immune system MP:0005387 9.4 NLRP3 PLCG2 PTGS1 PTGS2 SELE CMA1

Drugs & Therapeutics for Urticaria

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Clarinex 18 DESLORATADINE Schering-Plough February 2002

Drugs for Urticaria (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 411)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cetirizine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83881-51-0 2678
2
Desloratadine Approved, Investigational Phase 4,Phase 3,Phase 2 100643-71-8 124087
3
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 75614-87-8, 51-45-6 774
4
Levocetirizine Approved Phase 4,Phase 3,Phase 1,Phase 2 130018-77-8 1549000
5
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
6
Omalizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 242138-07-4
7
Hydroxyzine Approved Phase 4 68-88-2 3658
8
Cefazolin Approved Phase 4,Not Applicable 25953-19-9 656510 33255
9
Ebastine Approved, Investigational Phase 4 90729-43-4 3191
10
Fexofenadine Approved, Investigational Phase 4,Phase 2 83799-24-0 3348
11
Loratadine Approved, Investigational Phase 4,Phase 3,Phase 2 79794-75-5 3957
12
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
13
Clevidipine Approved, Investigational Phase 4 167221-71-8
14
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
15
Fluconazole Approved, Investigational Phase 4 86386-73-4 3365
16
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 1,Phase 2 22916-47-8 4189
17
Rivastigmine Approved, Investigational Phase 4 123441-03-2 77991
18
Praziquantel Approved, Investigational, Vet_approved Phase 4 55268-74-1 4891
19
Azelastine Approved Phase 4,Phase 3 58581-89-8 2267
20
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
21
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
22
Acetaminophen Approved Phase 4,Phase 3 103-90-2 1983
23
Icatibant Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 138614-30-9, 130308-48-4 71364
24
Zinc Approved, Investigational Phase 4 7440-66-6 23994
25
Dapsone Approved, Investigational Phase 4 80-08-0 2955
26
Tofacitinib Approved, Investigational Phase 4 477600-75-2
27
Menthol Approved Phase 4,Not Applicable 2216-51-5 16666
28
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 59-30-3 6037
29
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2 58-05-9 143 6006
30
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Not Applicable 50-14-6 5280793
31
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Not Applicable 1406-16-2
32
Histidine Approved, Nutraceutical Phase 4 71-00-1 6274
33
Bradykinin Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-82-2 439201
34
Lactitol Investigational Phase 4,Phase 2 585-86-4 3871
35 Anti-Allergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Cholinergic Agents Phase 4,Phase 3,Phase 2,Phase 1
37 Cholinergic Antagonists Phase 4,Phase 3,Phase 2
38 Histamine Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Histamine H1 Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Histamine H1 Antagonists, Non-Sedating Phase 4,Phase 3,Phase 2
41
Histamine Phosphate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-74-1 65513
42 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Anesthetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Anesthetics, Local Phase 4,Phase 3,Phase 2,Phase 1
45 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Anti-Asthmatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Antipruritics Phase 4,Phase 3,Phase 2
50 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 495)
# Name Status NCT ID Phase Drugs
1 The Efficacy and Safety of Desloratadine With Levocetirizine in Treatment of Chronic Idiopathic Urticaria Unknown status NCT00346606 Phase 4 Denosin® and Xyzal®
2 Ultrasound Guided Pectoral Nerve I and II Blocks in Multimodal Analgesia for Breast Surgery Unknown status NCT02672813 Phase 4
3 Omalizumab in Chronic Spontaneous Urticaria Patients Non Responding to Initial Standard antihistaminE Treatment Completed NCT02550106 Phase 4 OMALIZUMAB
4 Levocetirizine Plus Bed-Time Hydroxyzine in the Management of Corticodependent Chronic Urticaria Versus Levocetirizine Alone in High Doses Completed NCT01250652 Phase 4 Levocetirizine;Levocetirizine plus Hydroxyzine
5 Evaluation of the Inhibitory Effect of 5 Anti-Histamines in Urticaria Completed NCT01940393 Phase 4 Cetirizine;Desloratadine;Fexofenadine;Ebastine;Bilastine
6 A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria Completed NCT02392624 Phase 4 Omalizumab;Placebo
7 Desloratadine 5, 10 and 20mg in Patients With Cold Urticaria Completed NCT01444196 Phase 4 Desloratadine
8 A Study to Assess and Compare the Effects of 5 mg vs. 20 mg Desloratadine on the Development of Cold Urticaria Lesions Completed NCT00600847 Phase 4 desloratadine;desloratadine;placebo
9 Effect of Omalizumab (Xolair) on Basophils in Patients With Chronic Idiopathic Urticaria Completed NCT01701583 Phase 4 Omalizumab
10 Study for the Treatment of Chronic Idiopathic Urticaria With High Doses of AERIUS (Desloratadine) (Study P04849) Completed NCT00536380 Phase 4 5-mg Desloratadine;10-mg Desloratadine;20-mg Desloratadine
11 CUTE (Chronic Urticaria Treatment Evaluation) Completed NCT00264303 Phase 4 Levocetirizine;Desloratadine
12 A Comparison of Aerius Continuous Treatment Versus Aerius PRN for Chronic Idiopathic Urticaria (Study P03147) Completed NCT00783354 Phase 4 desloratadine;desloratadine
13 An Open-Label Study of the Effects of Desloratadine (Aerius.) Treatment on the Quality of Life of Patients With Chronic Idiopathic Urticaria (Study P02540) Completed NCT00795522 Phase 4 Desloratadine
14 A Comparative Double-Blind, Double- Dummy Study of Desloratadine (DL) 5 MG Once Daily, Cetirizine 10 MG Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (Study P03735) Completed NCT00751218 Phase 4 desloratadine;placebo;cetirizine
15 Effects of Bilastine on F1 Simulator Driving Performance in Patients Affected by Allergic Rhinitis and/or Urticaria Completed NCT02576041 Phase 4 Bilastine;Placebo
16 Postoperative Antibiotic Requirements Following Immediate Breast Reconstruction Completed NCT01244698 Phase 4 Cefadroxil discontinued early;Cefadroxil until drain removal
17 Clevidipine for Vasoreactivity Evaluation of the Pulmonary Arterial Bed Completed NCT01121458 Phase 4 Clevidipine
18 Safety and Efficacy of Benefix in Patients With Hemophilia B in Usual Care Settings in China Completed NCT02336178 Phase 4 Benefix
19 Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix TM) Administered in Healthy Adolescents Completed NCT00534638 Phase 4
20 Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma Completed NCT00267202 Phase 4 Placebo;Omalizumab;Immunotherapy;Immunotherapy
21 The Safety and Utility of Skin Testing With XOLAIR® (Omalizumab) and Placebo Omalizumab (Formulation Excipients) Completed NCT00777764 Phase 4 Cohort I;Cohort 2
22 Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis Completed NCT02180828 Phase 4 Clotrimazole vaginal tablet;Fluconazole
23 Convenience, Tolerability, and Safety of Change in the Administration of Rivastigmine From Capsules to a Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease Completed NCT00549601 Phase 4 Rivastigmine patch (4.6 mg/day switch to 9.5 mg/day);Rivastigmine patch (9.5 mg/day);Rivastigmine capsules (6 mg to 12 mg/day)
24 Evaluation of Praziquantel Dosage for Treatment of Schistosomiasis in Brazil Completed NCT00403611 Phase 4 Praziquantel 60 mg/kg;Praziquantel 40 mg/kg
25 Safety of Astepro 0.15% Nasal Spray and Astepro 0.1% Nasal Spray in Children Ages >6 Months to <6 Years With AR Completed NCT01880840 Phase 4 205.5 mcg of azelastine hydrochloride;137 mcg of azelastine hydrochloride
26 Use of an Antiemetic to Shorten the Length of Labor in Nulliparous Women Completed NCT01937234 Phase 4 Metoclopramide;Placebo
27 RCT (Randomized Controlled Trial) of IV Acetaminophen for Post Operative Vaginal Reconstruction Pain Completed NCT02043704 Phase 4 IV Acetaminophen
28 A Call Center During HAE Attacks (SOS HAE) Completed NCT01679912 Phase 4
29 Postmarketing Immunogenicity Study in HAE Subjects Treated With Berinert Completed NCT01467947 Phase 4
30 Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE Completed NCT01457430 Phase 4 Icatibant
31 A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE Completed NCT00914966 Phase 4
32 A Trial Evaluating a 7-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants. Completed NCT01250756 Phase 4
33 Exubera Large Simple Trial To Evaluate Long-Term Pulmonary And Cardiovascular Safety Completed NCT00359801 Phase 4 Randomization to Exubera (insulin human [rDNA origin] inhalation powder) or Usual Diabetes Care;Randomization to Exubera (insulin human [rDNA origin] inhalation powder) or Usual Diabetes Care
34 Role of Immunoglobulin E (IgE) Bearing Cells in Chronic Idiopathic Urticaria (CIU) Recruiting NCT03111628 Phase 4 Omalizumab
35 Treatment of Chronic Urticarial Unresponsive to H1-antihistamines With an Anti-IL5Ralpha Monoclonal Antibody Recruiting NCT03183024 Phase 4
36 Clinical Utility Of Genetic Screening For HLA-B*1301, On Susceptibility To Dapsone Hypersensitivity Syndrome Recruiting NCT02550080 Phase 4 Dapsone
37 Safety and Tolerability of Herpes Zoster Vaccine Rheumatologic Patients Recruiting NCT03016884 Phase 4
38 Treatment of Idiopathic Angioedema With Xolair as Add-on Therapy Recruiting NCT02966314 Phase 4 Omalizumab;Placebos
39 Reversal With Low Doses of Sugammadex in Patients Undergoing Non-cardiac Surgery Not yet recruiting NCT03460509 Phase 4 Sugammadex
40 Menthol for PDT Pain Not yet recruiting NCT02984072 Phase 4 Menthol;Aqueous Cream
41 A Comparative Double-blind, Double-dummy Study of Desloratadine (DL) 5 mg Once Daily, Cetirizine 10 mg Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (Study P03736) Terminated NCT00751166 Phase 4 Desloratadine;Cetirizine;placebo
42 A Study to Assess the Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (Cervarix) in Healthy Female Filipino Subjects Vaccinated According to the Prescribing Information From the Age of 10 Years Onwards. Terminated NCT00730847 Phase 4
43 Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated Angioedema Terminated NCT01574248 Phase 4 icatibant
44 Sustained Effect of Urticaria Remission With Relatively High Dose Vitamin D Supplementation After Omalizumab Discontinuation Withdrawn NCT02742805 Phase 4 Omalizumab
45 Ceftaroline in the Treatment of Bone and Joint Infections Withdrawn NCT02005068 Phase 4 Ceftaroline
46 C1-INH Compared to Placebo at the Time of Prodromal Symptoms for Hereditary Angioedema (HAE) Exacerbation Withdrawn NCT01151735 Phase 4 C-1-esterase;C-1-esterase;placebo
47 Efficacy of Levocetirizine Fourfold Dosage in Chronic Spontaneous Urticaria Unknown status NCT02372604 Phase 3 Levocetirizine (as levocetirizine dihydrochloride), 5mg ( then 20 mg) per day . Oral administration.;Levocetirizine, (as levocetirizine dihydrochloride) 20 mg ( then 5 mg) per day. Oral administration.
48 Efficacy and Safety of Omalizumab in Chronic Idiopathic Urticaria Unknown status NCT02166151 Phase 3 Omalizimab
49 Glucocorticoids With Antihistamines Versus Antihistamines in Acute Urticaria in Emergency Completed NCT02565680 Phase 2, Phase 3 placebo;prednisone
50 Bilastine Updosing in Chronic Spontaneous Urticaria Completed NCT02213367 Phase 3 Bilastine;Bilastine;Bilastin

Search NIH Clinical Center for Urticaria

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Urticaria

Genetic tests related to Urticaria:

# Genetic test Affiliating Genes
1 Urticaria 29

Anatomical Context for Urticaria

The Foundational Model of Anatomy Ontology organs/tissues related to Urticaria:

19
The Upper Dermis

MalaCards organs/tissues related to Urticaria:

41
Skin, Testes, Thyroid, Bone, T Cells, Brain, Liver

Publications for Urticaria

Articles related to Urticaria:

(show top 50) (show all 1806)
# Title Authors Year
1
Natural course of new-onset urticaria: Results of a 10-year follow-up, nationwide, population-based study. ( 29945815 )
2018
2
Natural course and prognostic factors of chronic urticaria in Korean children: A single center experience. ( 29888927 )
2018
3
Solar urticaria in 145 patients: Assessment of action spectra and impact on quality of life in adults and children. ( 29533487 )
2018
4
Treatment Patterns, Healthcare Resource Utilization, and Spending Among Medicaid-Enrolled Children with Chronic Idiopathic/Spontaneous Urticaria in the United States. ( 29429043 )
2018
5
Serum Sickness-like Reaction in a Pediatric Patient using Omalizumab for Chronic Spontaneous Urticaria. ( 29444344 )
2018
6
Omalizumab chronic spontaneous urticaria: efficacy, safety, predictors of treatment outcome and time to response. ( 29949781 )
2018
7
Bier anaemic spots, cyanosis with urticaria-like eruption (BASCULE) syndrome on trunk and upper limbs. ( 29943837 )
2018
8
Chronic spontaneous urticaria in children - a systematic review on interventions and comorbidities. ( 29392757 )
2018
9
Chronic inducible urticaria: a systematic review of treatment options. ( 29438771 )
2018
10
The Effect of Omalizumab on Hematological and Inflammatory Parameters in Patients with Chronic Spontaneous Urticaria. ( 29969297 )
2018
11
Effectiveness in the treatment of solar urticaria with omalizumab: Report of 7 cases. ( 29526307 )
2018
12
A Rare Case of Paediatric Bullous Spontaneous Acute Urticaria. ( 29953982 )
2018
13
Chronic urticaria in children may be different from adults. ( 29974980 )
2018
14
Occupational allergic rhinitis and contact urticaria caused by Gum Arabic in a candy factory worker. ( 29446105 )
2018
15
Successful treatment of refractory cholinergic urticaria with omalizumab. ( 29057464 )
2018
16
Schnitzler syndrome associated with hairy cell leukemia presenting with chronic urticaria and arthralgias. ( 29693079 )
2018
17
Economic Burden of the Inadequate Management of Allergic Rhinitis and Urticaria in Asian Countries Based on the GAA^LEN Model. ( 29949833 )
2018
18
Prevalence of drugs as triggers of exacerbations in chronic urticaria. ( 29956666 )
2018
19
Omalizumab for the Treatment of Solar Urticaria: Case Series and Systematic Review of the Literature. ( 29572192 )
2018
20
Overweight and obesity may play a role in the pathogenesis of chronic spontaneous urticaria. ( 29327369 )
2018
21
Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic/spontaneous urticaria: a systematic review of 'real-world' evidence. ( 29431518 )
2018
22
Urticaria Pigmentosa (Cutaneous Mastocytosis) ( 29494109 )
2018
23
Two-week intervals during omalizumab treatment may provide better symptom control in selected patients with chronic urticaria. ( 29410306 )
2018
24
Development and Validation of the Cholinergic Urticaria Quality of Life Questionnaire: CholU-QoL. ( 29369455 )
2018
25
Evaluating and managing chronic idiopathic urticaria in adults. ( 29889715 )
2018
26
Contact dermatitis with concomitant contact urticaria syndrome due to multiple ingredients of oxidative hair dye. ( 29866587 )
2018
27
Urticaria Induced by Ingestion of Anemonia sulcata. ( 29939146 )
2018
28
Malassezia infection associated with chronic spontaneous urticaria without angioedema: a report on five cases. ( 29945261 )
2018
29
Urticaria multiforme, an &amp;quot;erythema multiforme&amp;quot; simulator. ( 29398004 )
2018
30
The treatment outcomes and dose de-escalation of desloratadine up-dosing in chronic spontaneous urticaria. ( 29380864 )
2018
31
Food-Related Contact Dermatitis, Contact Urticaria, and Atopy Patch Test with Food. ( 29881951 )
2018
32
Use of skin biomarker profiles to distinguish Schnitzler syndrome from chronic spontaneous urticaria: results of a pilot study. ( 28580686 )
2018
33
Posttraumatic stress disorder, emotional suppression and psychiatric co-morbidity in patients with chronic idiopathic urticaria: a moderated mediation analysis. ( 29431522 )
2018
34
Omalizumab normalizes the gene expression signature of lesional skin in patients with chronic spontaneous urticaria: a randomized, double-blind, placebo-controlled study. ( 29974963 )
2018
35
Circulating soluble LIGHT/TNFSF14 is increased and associated with IL-8 concentration in chronic spontaneous urticaria. ( 29952668 )
2018
36
The role and relevance of mast cells in urticaria. ( 29431202 )
2018
37
Paediatric solar urticaria: A case series. ( 29315482 )
2018
38
A case of contact dermatitis and contact urticaria syndrome due to multiple allergens observed in a professional baseball player. ( 29395964 )
2018
39
Treatment response to omalizumab in patients with refractory chronic spontaneous urticaria. ( 29399789 )
2018
40
Real-World Characteristics and Treatment Patterns in Patients with Urticaria Initiating Omalizumab in the United States. ( 29952712 )
2018
41
Food-dependent cold urticaria: A new variant of physical urticaria. ( 29698807 )
2018
42
Efficacy of Oral Ruxolitinib in a Patient with Refractory Chronic Spontaneous Urticaria. ( 29978888 )
2018
43
Impact of chronic urticaria on quality of life and work in Japan: Results of a real-world study. ( 29897137 )
2018
44
The functional and structural alterations of the striatum in chronic spontaneous urticaria. ( 29379058 )
2018
45
Comorbidity of viral hepatitis and chronic spontaneous urticaria: A systematic review. ( 29786879 )
2018
46
Omalizumab treatment in patients with chronic inducible urticaria: AA systematic review of published evidence. ( 28751232 )
2018
47
Epidemiology of urticaria including physical urticaria and angioedema in Korea. ( 29742892 )
2018
48
Chronic urticaria revealing amebiasis. ( 29908957 )
2018
49
Coexistence of urticaria pigmentosa and thalassemia minor in a young adult. ( 29785323 )
2018
50
Global Burden of Urticaria: Insights from the 2016 Global Burden of Disease Study. ( 29438758 )
2018

Variations for Urticaria

ClinVar genetic disease variations for Urticaria:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 F12 NM_000505.3(F12): c.983C> G (p.Thr328Arg) single nucleotide variant Pathogenic rs118204456 GRCh37 Chromosome 5, 176831232: 176831232
2 F12 NM_000505.3(F12): c.983C> G (p.Thr328Arg) single nucleotide variant Pathogenic rs118204456 GRCh38 Chromosome 5, 177404231: 177404231

Expression for Urticaria

Search GEO for disease gene expression data for Urticaria.

Pathways for Urticaria

GO Terms for Urticaria

Cellular components related to Urticaria according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.61 AOC1 C1S F12 FCER2 HNMT PLCG2
2 extracellular space GO:0005615 9.23 AOC1 C1S CMA1 CPN1 F12 RNASE3

Biological processes related to Urticaria according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 cellular oxidant detoxification GO:0098869 9.5 LTC4S PTGS1 PTGS2
2 prostaglandin metabolic process GO:0006693 9.49 PTGS1 PTGS2
3 positive regulation of receptor internalization GO:0002092 9.48 PLCG2 SELE
4 lipoxygenase pathway GO:0019372 9.46 LTC4S PTGS2
5 prostaglandin biosynthetic process GO:0001516 9.43 PTGS1 PTGS2
6 protein processing GO:0016485 9.43 CMA1 CPN1 F12
7 peptide metabolic process GO:0006518 9.4 CMA1 CPN1
8 cyclooxygenase pathway GO:0019371 9.37 PTGS1 PTGS2
9 regulation of inflammatory response GO:0050727 9.26 CMA1 NLRP3 PTGS2 SELE
10 inflammatory response GO:0006954 9.17 ADGRE2 HRH1 MS4A2 NLRP3 PTGS1 PTGS2
11 cellular response to histamine GO:0071420 9.16 AOC1 HRH1

Molecular functions related to Urticaria according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 calcium ion binding GO:0005509 9.55 ADGRE2 AOC1 C1S F12 TPT1
2 peroxidase activity GO:0004601 9.26 PTGS1 PTGS2
3 prostaglandin-endoperoxide synthase activity GO:0004666 8.96 PTGS1 PTGS2
4 IgE binding GO:0019863 8.8 FCER1A FCER2 MS4A2

Sources for Urticaria

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....